Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marietta Kirchner

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Gait & Posture|October 5, 2013
Ellipse area calculations and their applicability in posturographyPatric Schubert, Marietta Kirchner
Biometrical Journal. Biometrische Zeitschrift|October 8, 2019
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpointHeiko Götte, Marietta Kirchner, Meinhard Kieser
Biometrical Journal. Biometrische Zeitschrift|September 6, 2018
Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performedStella Preussler, Meinhard Kieser, Marietta Kirchner
Journal of Biopharmaceutical Statistics|June 13, 2025
Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external controlHeiko Götte, Marietta Kirchner, Meinhard Kieser
Pharmaceutical Statistics|March 12, 2024
Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpointsMarietta Kirchner, Stefanie Schüpke, Meinhard Kieser
Journal of Biopharmaceutical Statistics|April 24, 2026
Estimation, testing and sample size calculation within the responder-stratified exponential survival modelSamuel Kilian, Marietta Kirchner, Meinhard Kieser
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
Statistics in Medicine|August 11, 2015
Utility-based optimization of phase II/III programsMarietta Kirchner, Meinhard Kieser, Heiko Götte, et al.
BMC Medical Research Methodology|October 10, 2020
Optimal designs for phase II/III drug development programs including methods for discounting of phase II resultsStella Erdmann, Marietta Kirchner, Heiko Götte, et al.
Pharmaceutical Statistics|April 28, 2018
Optimal planning of phase II/III programs for clinical trials with multiple endpointsMeinhard Kieser, Marietta Kirchner, Eva Dölger, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Gait & Posture|October 5, 2013
Ellipse area calculations and their applicability in posturographyPatric Schubert, Marietta Kirchner
Biometrical Journal. Biometrische Zeitschrift|October 8, 2019
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpointHeiko Götte, Marietta Kirchner, Meinhard Kieser
Biometrical Journal. Biometrische Zeitschrift|September 6, 2018
Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performedStella Preussler, Meinhard Kieser, Marietta Kirchner
Journal of Biopharmaceutical Statistics|June 13, 2025
Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external controlHeiko Götte, Marietta Kirchner, Meinhard Kieser
Pharmaceutical Statistics|March 12, 2024
Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpointsMarietta Kirchner, Stefanie Schüpke, Meinhard Kieser
Journal of Biopharmaceutical Statistics|April 24, 2026
Estimation, testing and sample size calculation within the responder-stratified exponential survival modelSamuel Kilian, Marietta Kirchner, Meinhard Kieser
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
Statistics in Medicine|August 11, 2015
Utility-based optimization of phase II/III programsMarietta Kirchner, Meinhard Kieser, Heiko Götte, et al.
BMC Medical Research Methodology|October 10, 2020
Optimal designs for phase II/III drug development programs including methods for discounting of phase II resultsStella Erdmann, Marietta Kirchner, Heiko Götte, et al.
Pharmaceutical Statistics|April 28, 2018
Optimal planning of phase II/III programs for clinical trials with multiple endpointsMeinhard Kieser, Marietta Kirchner, Eva Dölger, et al.
Pageof 8